辛伐他汀对高胆固醇血症大鼠APP、BACE蛋白表达的影响(4)
[11]Parsons CG，Ruitenberg M，Freitag CE，et al.Rammes G.MRZ-99030-A novel modulator of Abeta aggregation：I-Mechanism of action(MoA) underlying the potential neuroprotective treatment of Alzheimer′s disease，glaucoma and age-related macular degeneration(AMD)[J].Neuropharmacol，2015，92(21)：158-169.
[12]Iaccarino HF，Singer AC，Martorell AJ，et al.Gamma frequency entrainment attenuates amyloid load and modifies microgli[J].Nature，2016，540(32)：230-235.
[13]Ourdev D，Foroutanpay BV，Wang Y，et al.The Effect of Aβ1-42 Oligomers on APP Processing and Aβ1-40 Generation in Cultured U-373 Astrocytes[J].Neuro-degenerative diseases，2015，15(6)：361-368.
[14]Dobrowolska JA，Michener MS，Wu G，et al.CNS amyloid-beta，soluble APP-alpha and-beta kinetics during BACE inhibition[J].Neurosci，2014，34(24)：8336-8346.
[15]Tang Y，Peng Y，Liu J，et al.Early inflammation-associated factors blunt sterol regulatory element-binding proteins-1-mediated lipogenesis in high-fat diet-fed APP/PSEN1dE9 mouse model of Alzheimer′s diseas[J].J Neurochem，2015， 136(4)：791-803.
[16]Cui W，Sun Y，Wang Z，et al.Activation of liver X receptor decreases BACE1 expression and activity by reducing membrane cholesterol levels[J].Neurochem Res，2011，36(10)：1910-1921.
[17]Savage MJ，Holder DJ，Wu G，et al.Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer′s Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer′s Disease Neuroimaging Initiative-1 Baseline Cohort[J].JAD，2015，46(2)：431-440.
[18]Stromberg K，Eketjall S，Georgievska B，et al.Combining an amyloid-beta(Abeta)cleaving enzyme inhibitor with a gamma-secretase modulator results in an additive reduction of Abeta production [J].The FEBS journal，2015，282(1)：65-73.
[19]DeKosky ST.Statin therapy in the treatment of Alzheimer disease：what is the rationale？[J].Am J Med，2005，12(12)：48-53.
[20]Li G，Larson EB，Sonnen JA，et al.Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease[J].Neurology，2008，69(9)：878-885.
(收稿日期：2017-03-29 本文編辑：马 越), http://www.100md.com(梁倩 唐伟 刘文博 王威)
[12]Iaccarino HF，Singer AC，Martorell AJ，et al.Gamma frequency entrainment attenuates amyloid load and modifies microgli[J].Nature，2016，540(32)：230-235.
[13]Ourdev D，Foroutanpay BV，Wang Y，et al.The Effect of Aβ1-42 Oligomers on APP Processing and Aβ1-40 Generation in Cultured U-373 Astrocytes[J].Neuro-degenerative diseases，2015，15(6)：361-368.
[14]Dobrowolska JA，Michener MS，Wu G，et al.CNS amyloid-beta，soluble APP-alpha and-beta kinetics during BACE inhibition[J].Neurosci，2014，34(24)：8336-8346.
[15]Tang Y，Peng Y，Liu J，et al.Early inflammation-associated factors blunt sterol regulatory element-binding proteins-1-mediated lipogenesis in high-fat diet-fed APP/PSEN1dE9 mouse model of Alzheimer′s diseas[J].J Neurochem，2015， 136(4)：791-803.
[16]Cui W，Sun Y，Wang Z，et al.Activation of liver X receptor decreases BACE1 expression and activity by reducing membrane cholesterol levels[J].Neurochem Res，2011，36(10)：1910-1921.
[17]Savage MJ，Holder DJ，Wu G，et al.Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer′s Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer′s Disease Neuroimaging Initiative-1 Baseline Cohort[J].JAD，2015，46(2)：431-440.
[18]Stromberg K，Eketjall S，Georgievska B，et al.Combining an amyloid-beta(Abeta)cleaving enzyme inhibitor with a gamma-secretase modulator results in an additive reduction of Abeta production [J].The FEBS journal，2015，282(1)：65-73.
[19]DeKosky ST.Statin therapy in the treatment of Alzheimer disease：what is the rationale？[J].Am J Med，2005，12(12)：48-53.
[20]Li G，Larson EB，Sonnen JA，et al.Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease[J].Neurology，2008，69(9)：878-885.
(收稿日期：2017-03-29 本文編辑：马 越), http://www.100md.com(梁倩 唐伟 刘文博 王威)